

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60516	SERIAL NO. 10/572,671
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Johnson et al.	
		FILING DATE March 20, 2006	GROUP 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,313,126B1	11/6/01	Meagher et al.	514	249	
	US2003013708A1	1/16/03	Haeberlein et al.	514	231.5	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 03/080580 A2	10/2/03	PCT				
	WO 03/035061 A1	5/1/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Woolley et al. <i>Neuropharmacology</i> , Vol. 41: 210-219 (2001).
	Mitchell et al., <i>Pharmacol. & Therapeutics</i> , 108: 320-333 (2005).
	Chuang et al., <i>Alzheimer's & Dementia, The Journal of the Alzheimer's Association</i> , 2(3/Supp. 1): S631-S632 (2006).
	London Stock Exchange Announcement – GlaxoSmithKline (GSK) plc, Issued on Thursday, December 13, 2007, New York, New York.
	A Dose Ranging Study to Investigate the Efficacy and Safety of SB-742457 in Alzheimer's Disease. NCT ID NO: NCT00224497 (Verified 2007).
	SB-742457 and Donepezil in Alzheimer's Disease. NCT ID NO: NCT00348192 (2006).
	Garcia-Alloza et al. <i>Neuropsychopharmacology</i> , 29: 410-416 (2004).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	